Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation.

Anemia of inflammation (AI), the second most frequent form of anemia, complicates inflammatory and chronic diseases.[1][1] Although typically mild to moderate, AI is associated with increased morbidity and mortality.[1][1] One of the mechanisms contributing to the development of AI is a persistent